{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T10:43:17Z","timestamp":1758278597579,"version":"3.43.0"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>To evaluate Chinese long-term economic impact of universal human leukocyte antigen B (HLA-B)*58:01 genotyping-guided urate-lowering therapy or febuxostat initiation therapy for gout patients with mild to moderate chronic kidney disease (CKD) from perspective of healthcare system.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A Markov model embedded in a decision tree was structured including four mutually exclusive health states (uncontrolled-on-therapy, controlled-on-therapy, uncontrolled-off-therapy, and death). Mainly based on Chinese real-world data, the incremental costs per quality-adjusted life years (QALYs) gained were evaluated from three groups (universal HLA-B*58:01 testing strategy, and no genotyping prior to allopurinol or febuxostat initiation therapy) at 25-year time horizon. All costs were adjusted to 2021 levels based on Chinese Consumer Price Index and were discounted by 5% annually. One-way and probability sensitivity analysis were performed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Among these three groups, universal HLA-B*58:01 genotyping was the most cost-effective strategy in base-case analysis according to Chinese average willingness-to-pay threshold of $37\u2009654.50 per QALY. The based incremental cost-effectiveness ratio was $31784.55 per QALY, associated with 0.046 additional QALYs and $1463.81 increment costs per patient at a 25-year time horizon compared with no genotyping prior to allopurinol initiation strategy. Sensitivity analysis showed 64.3% robustness of these results.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>From Chinese perspective of healthcare system, HLA-B*58:01 genotyping strategy was cost-effective for gout patients with mild to moderate CKD in mainland China, especially in the most developed area, such as Beijing and Shanghai. Therefore, we suggest China\u2019s health authorities choose the genotyping strategy and make different recommendations according to the differences of local conditions.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/fpc.0000000000000488","type":"journal-article","created":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T16:50:33Z","timestamp":1675356633000},"page":"24-34","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["A lifetime economic research of universal HLA-B*58:01 genotyping or febuxostat initiation therapy in Chinese gout patients with mild to moderate chronic kidney disease"],"prefix":"10.1097","volume":"33","author":[{"given":"Yuan","family":"Hong","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Wuxi Children\u2019s Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xichuang","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Wuxi 9th People\u2019s Hospital affiliated to Soochow University and Wuxi Orthopaedic Hospital, Wuxi, Jiangsu"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiping","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Children\u2019s Hospital of Fudan University, National Children\u2019s Medical Center, Shanghai"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Wuxi 9th People\u2019s Hospital affiliated to Soochow University and Wuxi Orthopaedic Hospital, Wuxi, Jiangsu"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cong","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Wuxi 9th People\u2019s Hospital affiliated to Soochow University and Wuxi Orthopaedic Hospital, Wuxi, Jiangsu"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Wuxi Children\u2019s Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangfei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Children\u2019s Hospital of Fudan University, National Children\u2019s Medical Center, Shanghai"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Children\u2019s Hospital of Fudan University, National Children\u2019s Medical Center, Shanghai"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danli","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Wuxi Children\u2019s Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai","family":"feng Li","sequence":"additional","affiliation":[{"name":"Department of Joint Surgery, Wuxi 9th People\u2019s Hospital Affiliated to Soochow University and Wuxi Orthopaedic Hospital, Wuxi, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,12,9]]},"reference":[{"key":"R1-20250811","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/art.41247","article-title":"2020 American college of rheumatology guideline for the management of gout.","volume":"72","author":"FitzGerald","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"R2-20250811","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12916-017-0890-9","article-title":"Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options.","volume":"15","author":"Bardin","year":"2017","journal-title":"BMC Med"},{"key":"R3-20250811","doi-asserted-by":"crossref","first-page":"762820","DOI":"10.1155\/2015\/762820","article-title":"Prevalence of hyperuricemia and gout in mainland China from 2000 to 2014: a systematic review and meta-analysis.","volume":"2015","author":"Liu","year":"2015","journal-title":"Biomed Res Int"},{"key":"R4-20250811","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1093\/rheumatology\/kez476","article-title":"Global, regional and national burden of gout, 1990\u20132017: a systematic analysis of the Global burden of disease study.","volume":"59","author":"Xia","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"R5-20250811","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3899\/jrheum.151476","article-title":"Cost-effectiveness analysis for genotyping before allopurinol treatment to prevent severe cutaneous adverse drug reactions.","volume":"44","author":"Ke","year":"2017","journal-title":"J Rheumatol"},{"key":"R6-20250811","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJM199411103311906","article-title":"Severe adverse cutaneous reactions to drugs.","volume":"331","author":"Roujeau","year":"1994","journal-title":"N Engl J Med"},{"key":"R7-20250811","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1016\/j.jaip.2019.05.047","article-title":"Unique clinical characteristics and prognosis of allopurinol-induced severe cutaneous adverse reactions.","volume":"7","author":"Park","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R8-20250811","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/cpt.1377","article-title":"Hypersensitivity and cardiovascular risks related to allopurinol and febuxostat therapy in asians: a population\u2013based cohort study and meta\u2013analysis.","volume":"106","author":"Chen","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"R9-20250811","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1684\/ejd.2020.3713","article-title":"Clinical profile of cutaneous adverse drug reactions: a retrospective study of 1883 hospitalized patients from 2007 to 2016 in Shanghai, China.","volume":"30","author":"Yang","year":"2020","journal-title":"Eur J Dermatol"},{"key":"R10-20250811","first-page":"417","article-title":"Survey of acute kidney injury in hospitalized patients.","volume":"23","author":"Fang","year":"2007","journal-title":"Chin J Nephrol"},{"key":"R11-20250811","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12886-018-0694-5","article-title":"Social-economic analysis of patients with Sjogren\u2019s syndrome dry eye in East China: a cross\u2013sectional study.","volume":"18","author":"Yao","year":"2018","journal-title":"BMC Ophthalmol"},{"key":"R12-20250811","doi-asserted-by":"crossref","first-page":"81870","DOI":"10.18632\/oncotarget.13250","article-title":"Impact of HLA-B*58:01 allele and allopurinol-induced cutaneous adverse drug reactions: evidence from 21 pharmacogenetic studies.","volume":"7","author":"Wu","year":"2016","journal-title":"Oncotarget"},{"key":"R13-20250811","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/FPC.0000000000000334","article-title":"A retrospective investigation of HLA-B*5801 in hyperuricemia patients in a Han population of China.","volume":"28","author":"Cheng","year":"2018","journal-title":"Pharmacogenet Genomics"},{"key":"R14-20250811","doi-asserted-by":"crossref","first-page":"h4848","DOI":"10.1136\/bmj.h4848","article-title":"Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study.","volume":"351","author":"Ko","year":"2015","journal-title":"BMJ"},{"key":"R15-20250811","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.semarthrit.2016.10.009","article-title":"The cost-effectiveness of HLA-B*5801 screening to guide initial urate-lowering therapy for gout in the United States.","volume":"46","author":"Jutkowitz","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"R17-20250811","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar2978","article-title":"The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial.","volume":"12","author":"Becker","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"R19-20250811","first-page":"1","article-title":"Guideline for the diagnosis and management of hyperuricemia and gout in China (2019).","volume":"36","year":"2020","journal-title":"Chin J Endocrinol Metab"},{"key":"R20-20250811","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s40744-019-00173-8","article-title":"A randomized, double-blind, non-inferiority study of febuxostat versus allopurinol in hyperuricemic Chinese subjects with or without gout.","volume":"6","author":"Zhang","year":"2019","journal-title":"Rheumatol Ther"},{"key":"R21-20250811","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/1756-185X.12266","article-title":"An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.","volume":"17","author":"Huang","year":"2014","journal-title":"Int J Rheum Dis"},{"key":"R22-20250811","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/1756-185X.12648","article-title":"A phase 3, multicenter, randomized, allopurinol-controlled study assessing the safety and efficacy of oral febuxostat in Chinese gout patients with hyperuricemia.","volume":"18","author":"Xu","year":"2015","journal-title":"Int J Rheum Dis"},{"key":"R23-20250811","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s10549-014-3042-3","article-title":"Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer.","volume":"147","author":"Diaby","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"R24-20250811","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.clinthera.2012.12.013","article-title":"Cost-effectiveness of continuation maintenance pemetrexed after cisplatin and pemetrexed chemotherapy for advanced nonsquamous non\u2013small-cell lung cancer: estimates from the perspective of the Chinese health care system.","volume":"35","author":"Zeng","year":"2013","journal-title":"Clin Ther"},{"key":"R25-20250811","doi-asserted-by":"crossref","first-page":"163","DOI":"10.5414\/CP202629","article-title":"A study comparing the safety and efficacy of febuxostat, allopurinol, and benzbromarone in Chinese gout patients: a retrospective cohort study.","volume":"55","author":"Zhou","year":"2017","journal-title":"Int J Clin Pharmacol Ther"},{"key":"R26-20250811","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s13075-019-1976-x","article-title":"Baseline urate level and renal function predict outcomes of urate-lowering therapy using low doses of febuxostat and benzbromarone: a prospective, randomized controlled study in a Chinese primary gout cohort.","volume":"21","author":"Liang","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"R27-20250811","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1136\/annrheumdis-2014-205577","article-title":"Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin.","volume":"74","author":"Chung","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R28-20250811","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1073\/pnas.0409500102","article-title":"HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol.","volume":"102","author":"Hung","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"R29-20250811","doi-asserted-by":"crossref","first-page":"e94294","DOI":"10.1371\/journal.pone.0094294","article-title":"Cost-effectiveness analysis of HLA-B*5801 testing in preventing allopurinol-induced SJS\/TEN in Thai population.","volume":"9","author":"Saokaew","year":"2014","journal-title":"PLoS One"},{"key":"R30-20250811","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.3899\/jrheum.110092","article-title":"Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions.","volume":"38","author":"Chohan","year":"2011","journal-title":"J Rheumatol"},{"key":"R32-20250811","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/FPC.0000000000000359","article-title":"Utility of human leukocyte antigen-B*58.","volume":"29","author":"Ke","year":"2019","journal-title":"Pharmacogenet Genomics"},{"key":"R33-20250811","doi-asserted-by":"crossref","first-page":"617","DOI":"10.7326\/M14-0227","article-title":"Cost-effectiveness of allopurinol and febuxostat for the management of gout.","volume":"161","author":"Jutkowitz","year":"2014","journal-title":"Ann Intern Med"},{"key":"R34-20250811","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.kisu.2018.11.001","article-title":"China kidney disease network (CK-NET) 2015 annual data report.","volume":"9","author":"Zhang","year":"2019","journal-title":"Kidney Int Suppl (2011)"},{"key":"R35-20250811","first-page":"1353","article-title":"Cost-effectiveness analysis of HLA-B*58:01 gene polymorphism detection before gout patients using allopurinol or febuxostat.","volume":"29","author":"Li","year":"2018","journal-title":"China Pharmacy"},{"key":"R36-20250811","first-page":"2424","article-title":"Retrospective analysis of targeted treatment for drug-induced liver injury.","volume":"39","author":"Zhao","year":"2019","journal-title":"Chin Hosp Pharm J"},{"key":"R37-20250811","first-page":"334","article-title":"Cost-effectiveness of Allopurinol and Febuxostat in the Treatment of Chinese Patients with Gout.","volume":"10","author":"Jiao","year":"2016","journal-title":"Chin J Allergy Clin Immunol"},{"key":"R39-20250811","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.12998\/wjcc.v7.i13.1717","article-title":"Liver failure associated with benzbromarone: a case report and review of the literature.","volume":"7","author":"Zhang","year":"2019","journal-title":"World J Clin Cases"},{"key":"R40-20250811","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s10198-014-0617-1","article-title":"Cost-effectiveness of febuxostat in chronic gout.","volume":"15","author":"Beard","year":"2014","journal-title":"Eur J Health Econ"},{"key":"R41-20250811","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1185\/03007995.2015.1041895","article-title":"Utility values in diabetic kidney disease: a literature review.","volume":"31","author":"Kennedy-Martin","year":"2015","journal-title":"Curr Med Res Opin"},{"key":"R42-20250811","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/S0161-6420(03)00462-7","article-title":"Utility assessment among patients with dry eye disease.","volume":"110","author":"Schiffman","year":"2003","journal-title":"Ophthalmology"},{"key":"R43-20250811","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1542-0124(12)70043-5","article-title":"Utility assessment to measure the impact of dry eye disease.","volume":"4","author":"Buchholz","year":"2006","journal-title":"Ocul Surf"},{"key":"R44-20250811","doi-asserted-by":"crossref","first-page":"873","DOI":"10.2165\/11314750-000000000-00000","article-title":"Cost-effectiveness analysis of adjuvant therapy for operable breast cancer from a Chinese perspective: doxorubicin plus cyclophosphamide versus docetaxel plus cyclophosphamide.","volume":"27","author":"Peng","year":"2009","journal-title":"PharmacoEcon"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FPC.0000000000000488","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:32Z","timestamp":1754956832000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FPC.0000000000000488"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,9]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/fpc.0000000000000488","relation":{},"ISSN":["1744-6872"],"issn-type":[{"type":"print","value":"1744-6872"}],"subject":[],"published":{"date-parts":[[2022,12,9]]}}}